


PHARMACEUTICAL 2017

CALITHERA

Calithera Biosciences Inc. Rank 200 of 313







PHARMACEUTICAL 2017



Calithera Biosciences Inc. Rank 200 of 313

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 307% points. The greatest weakness of Calithera Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 212% points.

The company's Economic Capital Ratio, given in the ranking table, is -333%, being 84% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	53,561
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,453
Liabilities, Non-Current	0
Other Assets	336
Other Compr. Net Income	56
Other Expenses	0
Other Liabilities	437
Other Net Income	330
Property and Equipment	899
Research and Development	27,748
Revenues	0
Selling, General and Administrative Expense	10,586

Output Variable	Value in 1000 USD
Assets	54,796
Liabilities	4,890
Expenses	38,334
Stockholders Equity	49,906
Net Income	-38,004
Comprehensive Net Income	-37,976
Economic Capital Ratio	-333%

